Strategic Initiative

Slingshot members are tracking this corporate initiative:

Bristol-Myers Squibb and PsiOxus Therapeutics Announce Immuno-Oncology Clinical Collaboration to Evaluate the Combination of Opdivo and Enadenotucirev

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

PsiOxus Therapeutics


Additional Information

Additional Relevant Details Opdivo is a PD-1 immune checkpoint inhibitor currently approved in 50 countries globally for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy, in 50 countries globally for the treatment of patients with unresectable or metastatic melanoma as mono-or combination therapy, in 34 countries globally for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy and in the U.S. for the treatment of patients with classical Hodgkin’s Lymphoma (cHL) that has relapsed or progressed after autologous hematopoietic stem cell transplantation (HSCT) and post-transplantation brentuximab vedotin.PsiOxus’ enadenotucirev is an oncolytic group B adenovirus therapeutic that is given intravenously and is currently in Phase 1 clinical studies for multiple solid tumor types. Enadenotucirev is a virus that selectively replicates in tumor cells but not in normal cells. Such viruses promote anti-tumor responses through a dual mechanism of action that is dependent on selective tumor cell killing and the induction of systemic anti-tumor immunity. Preclinical data demonstrate that this approach is potentially applicable to a broad range of epithelially derived solid tumors, many of which have compelling unmet needs even when treated with checkpoint inhibitors.Under the terms of this agreement, Bristol-Myers Squibb will make a one-time upfront payment of $10 million to PsiOxus, and the parties will share development costs. PsiOxus will be responsible for conducting the Phase 1 study with patient recruitment expected to start in the third quarter of 2016. Additionally, the companies will work exclusively with each other on anti-PD-1/PD-L1 antagonist antibody and enadenotucirev combination regimens, and Bristol-Myers Squibb will have a time-limited right of exclusive negotiation for commercial rights to enadenotucirev.
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date:
Jun 30, 2016
Projected Implementation:
Q2, 2016
Relevance Tracked Until:
Q3, 2016
Related Projects Image
  • Don’t see a project related to the strategic initiative you care about?

Related Keywords Late-stage Cancer, Nivolumab, Opdivo, Metastatic Melanoma, Classical Hodgkin’s Lymphoma, Post-transplantation Brentuximab Vedotin, Pd-1 Immune Checkpoint Inhibitor, Nsclc, Enadenotucirev, Autologous Hematopoietic Stem Cell Transplant